Primal Kaur

2.5k citations

34 papers · 1.8k indexed · 1 hit paper · h-index 16

Impact in

Immunology top 5%
- Biosimilars and Bioanalytical Methods
- IL-33, ST2, and ILC Pathways
Immunology and Allergy top 5%
- Allergic Rhinitis and Sensitization

Papers in

Immunology 15
- Biosimilars and Bioanalytical Methods 11
Pediatrics, Perinatology and Child Health 9
- Pharmaceutical studies and practices 7

Co-authors: Janet M. Griffiths Gene Colice Gun Almqvist Åsa Hellqvist Karin Bowen Andrew Menzies‐Gow Sandhia Ponnarambil Michael E. Wechsler
Journals: Annals of the Rheumatic Diseases (5 papers)Respiratory Research (2 papers)Journal of Clinical Oncology (2 papers)Journal of Clinical Densitometry (2 papers)Osteoporosis International (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Primal Kaur

34 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma 2021 · 606 citations

Peers

Countries citing papers authored by Primal Kaur

Since Specialization

Citations

This map shows the geographic impact of Primal Kaur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Primal Kaur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Primal Kaur more than expected).

Fields of papers citing papers by Primal Kaur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Primal Kaur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Primal Kaur. The network helps show where Primal Kaur may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Primal Kaur, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Primal Kaur Line = papers co-authored together Primal Kaur links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults with Severe Asthma Hadeer Aboumosalem, Le Kieu Hiep, Christopher E. Brightling, Allen Anton, A Mottok, Tobias Welte, Janet M. Griffiths, N.S.K. Ramli, G. C. Crampton, Gun Almqvist, Primal Kaur, Tor Skärby, Gene Colice	2021	13
2	SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma Respiratory Research ·Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Gordon Biddle, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther García Gil	2020	60
3	NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma Respiratory Research ·Andrew Menzies‐Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Leah J. Kershner, Karin Bowen, Åsa Hellqvist, May Mo, Esther García Gil	2020	70
4	P132 Design of an adaptive, phase 2, placebo-controlled, dose-ranging study to assess the efficacy and safety of AMG 570 in subjects with active SLE and inadequate response to standard of care therapy Poster presentations ·Lei Zhou, Hui Wang, Tony T. Jiang, 信行大塚, Laurence E. Cheng, Elodie Assayag, Primal Kaur	2020	3
5	Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study Annals of the Rheumatic Diseases ·Stanley Cohen, Mark C. Genovese, Ernest Choy, Fernando Pérez-Ruiz, Alan K. Matsumoto, Karel Pavelká, José L. Pablos, 闫晓天, Paweł Hrycaj, Nan Zhang, William Shergy, Primal Kaur	2017	135
6	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study Journal of the American Academy of Dermatology ·Kim Papp, H. Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Węgłowska, Nan Zhang, Bruce Strober	2017	105
7	Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community BioDrugs ·Richárd Márkus, Jennifer Liu, Monica Ramchandani, N. West, Teresa L. Born, Primal Kaur	2017	84
8	A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab Annals of the Rheumatic Diseases ·Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richárd Márkus	2016	65
9	FRI0191 Biosimilar Candidate ABP 501: Additional Efficacy Analyses from The Phase 3 Study Annals of the Rheumatic Diseases ·Stanley Cohen, Huang Shuoqiao, Primal Kaur	2016	2
10	Results of functional testing and pharmacokinetics comparing ABP 215 to bevacizumab. Journal of Clinical Oncology ·Richárd Márkus, Primal Kaur, Vincent Chow, Nan Zhang, Teresa L. Born, 太田康晴, J M Plumridge, Jyoti Velayudhan, Monique Howard, Timothy Brady, Theresa J. Goletz	2015	6
11	Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study Menopause The Journal of The North American Menopause Society ·David L. Kendler, David Macarios, Michael Lillestol, Alfred H. Moffett, Sacha Satram‐Hoang, Jave-Suarez Luis, Primal Kaur, En‐Tzu Tang, Rachel B. Wagman, Rob Horne	2013	25
12	Early Onset Adenovirus Infection after Simultaneous Kidney–Pancreas Transplant American Journal of Transplantation ·Mukund Varma, Yaël B. Kushner, Dicken S. C. Ko, Tatsuo Kawai, Paulo N. Martins, Primal Kaur, Michihiko TUZITANI, Camille N. Kotton	2011	12
13	Disseminated Mycobacterium kansasii infection with hepatic abscesses in a renal transplant recipient Transplant Infectious Disease ·Primal Kaur, Jay A. Fishman, Joseph Misdraji, Mukund Varma, Camille N. Kotton	2011	13
14	Open-label, Crossover Study Evaluating the Adherence, Preference, and Satisfaction of Denosumab and Alendronate Treatment in Postmenopausal Women: Results of the Second Year of the Study Journal of Clinical Densitometry ·Nick Freemantle, David L. Kendler, Primal Kaur, Suresh Siddhanti, En‐Tzu Tang, David Macarios, Sacha Satram‐Hoang, Jeff Borenstein, Michael R. McClung	2011	1
15	Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate Osteoporosis International ·(unknown), David L. Kendler, Michael R. McClung, Nick Freemantle, Michael Lillestol, Alfred H. Moffett, Jeff Borenstein, Sacha Satram‐Hoang, Yuching Yang, Primal Kaur, David Macarios, Suresh Siddhanti	2010	84
16	Microscopic Polyangiitis Presenting as Early Cardiac Tamponade JCR Journal of Clinical Rheumatology ·Primal Kaur, Laura N. Driessen, Jiayi Shi, S. Dabral	2010	4
17	Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients Clinical Rheumatology ·龙承学, Primal Kaur, 暁子齋藤, Steven Berney	2009	66
18	Infiltration of Histiocytes and Multinucleated Giant Cells in the Myocardium of a Patient With Multicentric Reticulohistiocytosis JCR Journal of Clinical Rheumatology ·東邦和, Harvey Sasken, Primal Kaur	2009	3
19	Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports Clinical Rheumatology ·Primal Kaur, 暁子齋藤, Steven Berney	2008	28
20	Successful Etanercept Use in an HIV-Positive Patient With Rheumatoid Arthritis JCR Journal of Clinical Rheumatology ·Primal Kaur, 暁子齋藤, Steven Berney	2007	34

About Primal Kaur

Primal Kaur is a scholar working on Immunology, Pediatrics, Perinatology and Child Health, Family Practice, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 34 papers that have together received 1.8k indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Pharmaceutical studies and practices (7 papers), Asthma and respiratory diseases (6 papers), Rheumatoid Arthritis Research and Therapies (5 papers), Bone health and treatments (4 papers), CAR-T cell therapy research (3 papers) and Dermatology and Skin Diseases (3 papers). The work is most often cited by research in Immunology (730 citations), Immunology and Allergy (197 citations), Orthopedics and Sports Medicine (275 citations), Physiology (670 citations) and Rheumatology (242 citations). Primal Kaur has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Janet M. Griffiths, Gene Colice, Gun Almqvist, Åsa Hellqvist, Karin Bowen, Andrew Menzies‐Gow, Sandhia Ponnarambil, Michael E. Wechsler, Elliot Israel and Jonathan Corren. Their work appears in journals such as Annals of the Rheumatic Diseases, Respiratory Research, Journal of Clinical Oncology, Journal of Clinical Densitometry and Osteoporosis International.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact